{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:22:48Z","timestamp":1780701768263,"version":"3.54.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The American College of Rheumatology (ACR), in conjunction with the American College of Chest Physicians (CHEST), recently published clinical practice guidelines for the treatment of adults with systemic autoimmune rheumatic disease-associated ILD, including SSc-ILD. Herein, we summarize evidence from randomized trials evaluating the safety and efficacy of pharmacologic therapies for the treatment of SSc-ILD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In this review, we present findings from recent randomized controlled trials in SSc-ILD. The pharmacologic therapies discussed include immunosuppressive medications (mycophenolate, cyclophosphamide, rituximab, and tocilizumab) and antifibrotic medications (nintedanib and pirfenidone).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Randomized trials provide an evidence base for the SSc-ILD treatment recommendations put forth in the ACR\/CHEST Guidelines for the treatment of ILD in people with systemic autoimmune rheumatic diseases. These guidelines will help inform clinical practice and highlight areas in which further research is needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001049","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T12:10:48Z","timestamp":1724847048000},"page":"420-426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results"],"prefix":"10.1097","volume":"36","author":[{"given":"Sindhu R.","family":"Johnson","sequence":"first","affiliation":[{"name":"Toronto Scleroderma Program, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana J.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.rdc.2022.06.006","article-title":"Environmental risks for systemic sclerosis","volume":"48","author":"Alahmari","year":"2022","journal-title":"Rheum Dis Clin North Am"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3899\/jrheum.140006","article-title":"The effect of male sex on survival in systemic sclerosis","volume":"41","author":"Hussein","year":"2014","journal-title":"J Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3899\/jrheum.180042","article-title":"Ethnic variations in systemic sclerosis disease manifestations, internal organ involvement, and mortality","volume":"46","author":"Al-Sheikh","year":"2019","journal-title":"J Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/acr.25347","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.071169","article-title":"Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma","volume":"36","author":"Johnson","year":"2009","journal-title":"J Rheumatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol Int"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2\u200ayears in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/acr2.11483","article-title":"Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks: data from a randomized controlled trial","volume":"4","author":"Assassi","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"(suppl 9)","key":"R23-20250526","article-title":"Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III [abstract]","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:18:34Z","timestamp":1748294314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001049","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}